New Zealand markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
64.27+1.63 (+2.60%)
At close: 04:04PM EDT
64.54 +0.27 (+0.42%)
After hours: 07:30PM EDT
Full screen
Loading interactive chart…
  • Motley Fool

    2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch

    According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.

  • Zacks

    Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses

    Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.

  • Zacks

    Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

    Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.